S9 Ep15: FDA Approval Insights: Glofitamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Dr Carlo-Stella discusses the FDA approval of glofitamab in relapsed/refractory DLBCL, key efficacy and safety findings from the NP30179 trial, and the benefits of glofitamab’s mechanism of action.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.